Pietro Gentile1, Ashutosh Kothari2, Donato Casella3, Claudio Calabrese4. 1. Department of Surgical Science, University of Rome Tor Vergata, Rome, Italy. 2. Guy's Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom. 3. Department of Oncologic and Reconstructive Breast Surgery, "Breast Unit Integrata di Livorno, Cecina, Piombino, Elba, Azienda USL Toscana Nord Ovest," Livorno, Italy. 4. Chief of the San Rossore Breast Unit, Pisa, Italy.
Abstract
BACKGROUND: Fat graft enhanced with adipose-derived stem cells (FG-e-ASCs) has been utilized in outcomes of radiotherapy after mastectomy, breast soft tissue defects, ulcers, and loss of substance. The authors present their experience utilizing FG-e-ASCs in breast augmentation. OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of a study group (SG) regarding utilization of FG-e-ASCs in breast augmentation for aesthetic improvement, comparing the results with a control group (CG). METHODS: A total of 46 patients affected by breast hypoplasia were treated with FG-e-ASCs, comparing results with those of a CG (n = 30) treated with fat graft not enhanced with adipose-derived stem cells (FG-ne-ASCs). The preoperative evaluation included a complete clinical evaluation, a photographic assessment, magnetic resonance imaging of the soft tissue, ultrasound, and mammography. Postoperative follow-up took place at 1, 3, 7, 12, 24, and 48 weeks and then annually. RESULTS: The patients treated with FG-e-ASCs showed 58% maintenance of the contour restoring and of 3-dimensional (3D) volume after 3 years compared with the patients of the CG treated with FG-ne-ASCs, who showed 29% maintenance. In 67.4% (n = 31) of breast augmentations treated with FG-e-ASCs, we observed a restoration of the breast contour and an increase of 10.3 mm in the 3D volume after 36 months, which was observed in only 20.0% (n = 6) of patients in the CG treated with FG-ne-ASCs. Volumetric persistence in the SG was higher than that in the CG (P < 0.0001 SG vs CG). CONCLUSIONS: Utilization of FG-e-ASCs was safe and effective in this series of cases performed.
BACKGROUND: Fat graft enhanced with adipose-derived stem cells (FG-e-ASCs) has been utilized in outcomes of radiotherapy after mastectomy, breast soft tissue defects, ulcers, and loss of substance. The authors present their experience utilizing FG-e-ASCs in breast augmentation. OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of a study group (SG) regarding utilization of FG-e-ASCs in breast augmentation for aesthetic improvement, comparing the results with a control group (CG). METHODS: A total of 46 patients affected by breast hypoplasia were treated with FG-e-ASCs, comparing results with those of a CG (n = 30) treated with fat graft not enhanced with adipose-derived stem cells (FG-ne-ASCs). The preoperative evaluation included a complete clinical evaluation, a photographic assessment, magnetic resonance imaging of the soft tissue, ultrasound, and mammography. Postoperative follow-up took place at 1, 3, 7, 12, 24, and 48 weeks and then annually. RESULTS: The patients treated with FG-e-ASCs showed 58% maintenance of the contour restoring and of 3-dimensional (3D) volume after 3 years compared with the patients of the CG treated with FG-ne-ASCs, who showed 29% maintenance. In 67.4% (n = 31) of breast augmentations treated with FG-e-ASCs, we observed a restoration of the breast contour and an increase of 10.3 mm in the 3D volume after 36 months, which was observed in only 20.0% (n = 6) of patients in the CG treated with FG-ne-ASCs. Volumetric persistence in the SG was higher than that in the CG (P < 0.0001 SG vs CG). CONCLUSIONS: Utilization of FG-e-ASCs was safe and effective in this series of cases performed.
Authors: Nesrine Ebrahim; Arigue A Dessouky; Ola Mostafa; Amira Hassouna; Mohamed M Yousef; Yasmin Seleem; Eman Abd El Aziz M El Gebaly; Mona M Allam; Ayman Samir Farid; Bayan A Saffaf; Dina Sabry; Ahmed Nawar; Ahmed A Shoulah; Ahmed H Khalil; Sami F Abdalla; Mohamed El-Sherbiny; Nehal M Elsherbiny; Rabab F Salim Journal: Stem Cell Res Ther Date: 2021-07-13 Impact factor: 6.832
Authors: Sandeep Adem; Darren B Abbas; Christopher V Lavin; Evan J Fahy; Michelle Griffin; Nestor M Diaz Deleon; Mimi R Borrelli; Shamik Mascharak; Abra H Shen; Ronak A Patel; Michael T Longaker; Rahim S Nazerali; Derrick C Wan Journal: Adv Wound Care (New Rochelle) Date: 2021-09-06 Impact factor: 4.947
Authors: Janaína José Dos Santos Machado; Bernard Gomes Piñeiro; Isalira Peroba Ramos; Sergio Augusto Lopes de Souza; Bianca Gutfilen; Maria Helena Nicola; Paulo Roberto Cotrim de Souza; Eduardo Cruz; Regina Coeli Goldenberg Journal: Stem Cells Int Date: 2020-02-14 Impact factor: 5.443